TrialPloS one2021

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.

Qiao Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.